Cited by 545Diabetes Treatment and ManagementBone health and osteoporosis researchDiabetes, Cardiovascular Risks, and Lipoproteins

Rosiglitazone-Associated Fractures in Type 2 Diabetes

Open access
Kahn, Steven E., Zinman, Bernard, Lachin, John M., Haffner, Steven M., Herman, William H., Holman, Rury R., Kravitz, Barbara G., Yu, Dahong +4 more·2008·Diabetes Care

Abstract

OBJECTIVE—The purpose of this study was to examine possible factors associated with the increased risk of fractures observed with rosiglitazone in A Diabetes Outcome Progression Trial (ADOPT). RESEARCH DESIGN AND METHODS—Data from the 1,840 women and 2,511 men randomly assigned in ADOPT to rosiglitazone, metformin, or glyburide for a median of 4.0 years were examined with respect to time to first fracture, rates of occurrence, and sites of fractures. RESULTS—In men, fracture rates did not differ between treatment groups. In women, at least one fracture was reported with rosiglitazone in 60 patients (9.3% of patients, 2.74 per 100 patient-years), metformin in 30 patients (5.1%, 1.54 per 100 patient-years), and glyburide in 21 patients (3.5%, 1.29 per 100 patient-years). The cumulative incidence (95% CI) of fractures in women at 5 years was 15.1% (11.2–19.1) with rosiglitazone, 7.3% (4.4–10.1) with metformin, and 7.7% (3.7–11.7) with glyburide, representing hazard ratios (95% CI) of 1.81 (1.17–2.80) and 2.13 (1.30–3.51) for rosiglitazone compared with metformin and glyburide, respectively. The increase in fractures with rosiglitazone occurred in pre- and postmenopausal women, and fractures were seen predominantly in the lower and upper limbs. No particular risk factor underlying the increased fractures in female patients who received rosiglitazone therapy was identified. CONCLUSIONS—Further investigation into the risk factors and underlying pathophysiology for the increased fracture rate in women taking rosiglitazone is required to relate them to preclinical data and better understand the clinical implications of and possible interventions for these findings.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc07-2270

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Snedecor GW, Cochran WG: Statistical Methods. 7th ed. Ames, Iowa, Iowa State University Press, 1980

Cited by

Sorted by citations

Authors
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., Viberti, G., & for the A Diabetes Outcome Progression Trial (ADOPT) Study Group
Affiliations
  • University of Washington (US)
  • Mount Sinai Hospital (CA)
  • George Washington University (US)
  • The University of Texas at San Antonio Health Science Center (US)
  • University of Michigan (US)
  • Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
  • GlaxoSmithKline (United States) (US)
  • King's College London (GB)
Venue
Diabetes Care
Published
2008-05-01
Volume
31
Issue
5
Pages
845-851
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2099673402
Cited by
537
References
22
Citations by year
2026: 7 · 2025: 10 · 2024: 10 · 2023: 11 · 2022: 17 · 2021: 30 · 2020: 18 · 2019: 19 · 2018: 36 · 2017: 31 · 2016: 31 · 2015: 31 · 2014: 40 · 2013: 43 · 2012: 41
FWCI
39.37
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Funders
GlaxoSmithKline
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
rosiglitazone, fracture, type 2 diabetes, ADOPT trial, metformin, glibenclamide, sex differences, women, fracture risk factors, bone fragility, thiazolidinediones
MeSH terms
Rosiglitazone, Aged, Diabetes Mellitus, Type 2, Female, Glyburide, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Treatment Outcome, Age of Onset, Disease Progression, Thiazolidinediones, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review